Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Pilot
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
A new flu vaccine which is injected into the skin instead of into the muscle has recently
been approved by the Food and Drug Administration for vaccination of the general population
including patients with atopic dermatitis (AD). This new vaccine has been shown to work as
well as the vaccine which is injected into muscle when tested in people without atopic
dermatitis. The primary endpoint of the study is to estimate the variance of the log fold
change from baseline in HAI antibody titers for non-atopic controls and participants with
atopic dermatitis without a history of eczema herpeticum (ADEH-), following administration of
a single dose of the seasonal 2011-2012 Fluzone® Intradermal vaccine.
Phase:
Early Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)